The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...
Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront ...
Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...
Lilly filed a lawsuit Nov. 14 against HHS head Xavier Becerra and the Health Resources and Services Administration for blocking a plan to change its 340B program from immediate discounts to offering ...
Key Takeaways Eli Lilly has joined Johnson & Johnson in filing a lawsuit against the federal government over a decades-old ...
Eli Lilly sued the Health Resources and Services Administration (HRSA) for allegedly blocking the pharma giant's proposal to ...
Eli Lilly (LLY) files lawsuit against U.S. health agency over 340B Program rebates, alleging arbitrary blockage of its cash ...
The case centers on the federal 340B program, in which drugmakers provide discounts to eligible healthcare providers that ...
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...
Eli Lilly is now the second drugmaker to propose a rebate model for 340B drug price discounts — and the second to ...
Wolfe Research analyst Alexandria Hammond initiated coverage of Johnson & Johnson (JNJ) with an Outperform rating and $190 price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback